Up +10% premarket, this AI-picked biotech heads into Q3 after a 533% EPS surprise

November has seen timely calls across tech, energy, and healthcare — delivering a dozen double-digit winners just days into the month. Standout performers include CONMED (NYSE:CNMD) up +21.16%, LivaNova PLC (NASDAQGS:LIVN) up +19.27%, and Canadian Solar Inc (NASDAQGS:CSIQ) up +16.41% in November alone.

These returns add to a long list of ongoing picks extending gains in recent months. Just this morning, as US markets reopen, one high-conviction biotech player is surging +10.38% in pre-market trading (at the time of writing) to $11.80. The move comes as shares build momentum ahead of the company’s Q3 earnings report scheduled after the bell tonight, following a blowout second quarter that produced a massive 533% earnings surprise.

And these wins are not alone. Here are some of the other massive gains members are currently sitting on since their stocks were first selected:

• Everforth (NYSE:EFOR): +110.59% since picked
• Delek US Holdings (NYSE:DK): +74.53% since picked
• Consensus Cloud Solutions (NASDAQGS:CCSI): +74.06% since picked
• Nucor (NYSE:NUE): +68.67% since picked
• Amneal Pharmaceuticals (NASDAQGS:AMRX): +54.65% since picked

Among many more!

Still not a member? Then here’s your chance to get the full list NOW:

• App users can subscribe here
• Web users can subscribe here

Which biotech standout is up 10% premarket?

That stock is Puma Biotechnology Inc. (NASDAQGS:PBYI). The biopharmaceutical firm is rallying ahead of its third-quarter financial release after previously crushing Q2 consensus estimates with diluted EPS of $0.16 against expectations of just $0.03 (a 533%+ beat) on revenue of $56.5 million. The company’s lead commercial therapy, NERLYNX, achieved two consecutive years of rising U.S. demand—an unprecedented milestone in the drug’s history. Combined with a balance sheet that is now completely debt-free and upwardly revised full-year guidance, Puma is drawing aggressive premarket accumulation.

ProPicks AI was built for exactly this — applying investor-grade financial research and machine-learning models to more than 60,000 stocks worldwide to find the companies where fundamentals and growth outlook are pointing to outsized moves before the broader market catches on.

What our models identified in Puma Biotechnology before the surge

Our machine learning engine selected Puma Biotechnology as a high-conviction setup driven by rising price momentum, accelerating profitability, and an attractive valuation window.

Here is what the ML engine saw before the move:

• Profitable Growth & Fair Value Upside: The stock has surged ~80% over the past year (up 116% across broader trailing windows) and gained ~60% over the last six months. Despite that rally, shares continued to trade well below InvestingPro’s Fair Value estimate of $12.55 (over 17% upside from previous close), backed by strong free cash flow yield and a healthy profitability profile.
• Standout Q2 Beat & Raised Guidance: Puma decisively returned to profitability in Q2 2026 after a Q1 loss, generating $56.5 million in revenue and $8.2 million in GAAP net profit ($0.16 per share vs. $0.03 expected). Management backed up the operational beat by lifting full-year 2026 NERLYNX product revenue guidance to $205–$209 million and net income to $17–$20 million.
• Debt-Free Balance Sheet & Rising Demand: Commercial execution on NERLYNX delivered sequential revenue expansion of 27.6% alongside two consecutive years of U.S. demand gains. Concurrently, Puma eliminated its outstanding obligations following its final Athyrium loan repayment, ending the quarter debt-free with $93.9 million in cash to support ongoing Phase II clinical pipeline development (including alisertib) without dilutive capital pressure.

Our AI models provide the same detailed rationale for every stock they select or remove, so members know exactly what the data showed at the time.

Backed by professional-grade financial intelligence, our monthly-updated list of tech picks has absolutely crushed the broader market, posting a +169.88% return since launching in November 2023. That is an incredible +88.37% outperformance over the benchmark S&P 500.

*These are real-world numbers, recorded since the official launch of our AI models in November 2023.

That is the power of moving out of overextended names and finding fresh value before the crowd does. The work for October is done, and the next cycle has already begun.

A New List of AI-Picked Stocks for November IS NOW LIVE

With ProPicks, subscribers don’t just receive a list of tickers. They gain access to the precise rationale behind every single addition and removal across our strategies, helping investors make informed, data-backed decisions before the broader market reacts.

Do not miss the opportunity to review the full list of November picks and see exactly where the smart money is moving next.

As part of our Early Bird Sale, you can secure an InvestingPro subscription for up to 55% off!

• Already a member? Jump straight to the FULL list of November picks HERE.
• Not yet a member? Here’s your opportunity to access the full list now
  • App users can subscribe here
  • Web users can subscribe here

How the AI Stock Picker Works

At the beginning of each month, our proprietary AI system evaluates thousands of global equities using a complex blend of historical data, valuation signals, and forward-looking growth metrics.

By processing more than 15 years of financial data across more than 150 quantitative models, the engine identifies up to 20 high-conviction stocks per strategy based on their projected medium-term upside potential.

Every month, these strategies undergo a strict rebalancing process. New opportunities are added, strong performers are retained, and stocks that no longer meet the criteria are removed.

To consistently track performance, each strategy utilizes equal weighting across all selected stocks. While investors are free to adjust their own allocations, this structure provides a transparent benchmark for evaluating overall model performance.

The objective is to systematically reposition capital toward the strongest opportunities as market conditions evolve.

Disclaimer: Subscription prices mentioned in articles are accurate at the time of publication. We regularly test different offers for our members, which may vary by region.